Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis: A Pilot Study With 20 Patients
Verified date | March 2021 |
Source | University of Ulm |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
During the course of ALS most patients develop swallowing deficits. In this pilot study we investigate if dysphagia in ALS can be improved by Pharyngeal Electrical Stimulation (PES). PES is Communauté Européenne (CE-) certificated and has been approved for treatment of neurological, oropharyngeal dysphagia. During PES, electrical stimuli are applied at the pharynx via a nasogastral tube with the aim of triggering reorganization processes in damaged brain structures. There is evidence of a positive effect of PES in Stroke and Multiple Sclerosis patients.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 21, 2020 |
Est. primary completion date | July 21, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - possible, probable or definite ALS according to the revised El Escorial criteria (Brooks et al. 2000) - age >18 years - able to understand all information and to give full consent according to good clinical practice (GCP) - moderate ot severe dysphagia, defined by a mean value (all consistencies) of 4 Exclusion Criteria: - concurrent participation in another interventional trial - tracheostomy - severe psychiatric disorder or clinically manifest dementia - pulmonal or cardial disorder which constitutes a risk when inserting the tube into the pharynx - permanent cardiac pacemaker or defibrillator |
Country | Name | City | State |
---|---|---|---|
Germany | University of Ulm | Ulm |
Lead Sponsor | Collaborator |
---|---|
University of Ulm |
Germany,
Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Penetration Aspiration Scale (PAS) Score | Degree of Penetration and Aspiration evaluated by fiberendoscopic evaluation of swallowing (FEES) | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Swallowing-Quality of Life Score (SWAL-QOL) | swallowing-specific quality of life questionnaire | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Schluckbeeinträchtigungs-Skala (SBS) Score | Clinical scale to evaluate severity of dysphagia | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Functional Oral Intake Scale (FOIS) Score | Clinical scale to evaluate the impairment of oral food intake | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Dysphagia Severity Rating Scale (DSRS) Score | Clinical scale to evaluate severity of dysphagia | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R) | Clinical scale to evaluate the severity of symptoms in ALS | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 | |
Secondary | Frequency of Adverse Events | Frequency of Adverse Events | day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |